ArticleVeterinary research communications2026
Maternal antibody-mediated protection against chicken astrovirus: efficacy of novel inactivated vaccine.
Article in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chicken astrovirus (CAstV) infections cause significant economic losses in global poultry production through nephritis, enteritis, and growth retardation, yet commercial vaccines remain unavailable. This study evaluated a novel inactivated CAstV vaccine's capacity to induce protective maternal antibodies in specific-pathogen free breeder chickens and subsequent progeny protection. One hundred SPF breeder chickens received two dose vaccination (10 and 16 weeks) with inactivated vaccine containing Genogroup B strain IP2024-00664 (GenBank: PX146716.1, complete ORF-2 capsid protein gene, 2,247 bp). Comprehensive serological monitoring used validated ELISA protocols. Progeny underwent controlled challenges at 3 days post hatch with homologous IP2024-00664 and heterologous ASN/CAstV/EG/2025 (nephropathogenic Genogroup B strains) using 10 chicks per group. Endpoints included clinical protection, viral suppression, histopathological changes, and economic parameters analyzed using Cox proportional hazards models, Kaplan-Meier survival analysis, and cost effectiveness modeling. Vaccinated breeders demonstrated exceptional immunological responses with peak antibody titers of 14,350 ± 1,892 versus baseline 35 ± 8 (P < 0.001). Maternal antibody transfer ratio reached 125%. Progeny achieved complete clinical protection with 100% survival rates (20/20) against both challenges compared to control groups showing 0% survival (0/10, heterologous challenge) and 30% survival (3/10, homologous challenge) (P < 0.001). Quantitative RT-PCR confirmed functional sterilizing immunity with viral RNA levels below the assay detection limit in vaccinated groups. Cost effectiveness analysis revealed favorable return on investment (base-case ROI: 187% per protected bird; sensitivity range: 62-312%) with break even at 0.27% mortality prevention. This inactivated CAstV vaccine successfully induced high titer, transferable maternal antibodies providing functional sterilizing immunity against phylogenetically distinct nephropathogenic challenges.
Indexed as
Identifiers
42301581What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.